Enorama Pharma AB (ERMA) — Cash Flow-to-Debt Ratio
Enorama Pharma AB (ERMA) has a Cash Flow-to-Debt Ratio of -0.20x as of March 2026, meaning its operating cash flow of Skr-12.09 Million could theoretically repay 0% of its total liabilities (Skr59.58 Million) in one year. Check total reinvestment intensity of Enorama Pharma AB to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Enorama Pharma AB Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Enorama Pharma AB across 12 annual periods. Also explore Enorama Pharma AB total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Enorama Pharma AB (2014–2025)
Year-by-year debt coverage analysis for Enorama Pharma AB. For market capitalisation and broader financial context, see Enorama Pharma AB (ERMA) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.87x | Skr-59.26 Million | Skr31.71 Million | ▲ +57.7% |
| 2024 | -4.41x | Skr-35.70 Million | Skr8.09 Million | ▼ -58.4% |
| 2023 | -2.79x | Skr-41.35 Million | Skr14.85 Million | ▼ -45.3% |
| 2022 | -1.92x | Skr-32.96 Million | Skr17.20 Million | ▼ -87.9% |
| 2021 | -1.02x | Skr-30.16 Million | Skr29.58 Million | ▼ -73.5% |
| 2020 | -0.59x | Skr-23.00 Million | Skr39.13 Million | ▲ +21.7% |
| 2019 | -0.75x | Skr-26.56 Million | Skr35.40 Million | ▼ -22.5% |
| 2018 | -0.61x | Skr-13.36 Million | Skr21.81 Million | ▲ +25.3% |
| 2017 | -0.82x | Skr-6.67 Million | Skr8.13 Million | ▲ +39.0% |
| 2016 | -1.34x | Skr-6.11 Million | Skr4.55 Million | ▼ -840.8% |
| 2015 | 0.18x | Skr480.00K | Skr2.64 Million | ▼ -38.9% |
| 2014 | 0.30x | Skr307.00K | Skr1.03 Million | — |